February is National Heart Month. Atrial fibrillation is a common condition in older demographics, but what is A-Fib? In this segment, Dr. Rudy Evanich from Bellin Health discusses what to ...

Compared with rivaroxaban, abelacimab is associated with fewer bleeding events in patients with AF and moderate to high risk for stroke.

In February 2024, Corewell Health introduced pulsed field ablation, a treatment procedure significantly safer than previous AFib treatments, at several of its Michigan hospitals. PFA applies a ...

People who regularly floss their teeth (one or more times per week) may lower their risk of stroke caused by a blood clot traveling from the heart and a stroke associated with an irregular heartbeat ...

PDUFA date of March 27, 2025 for CARDAMYST™ (etripamil) nasal spray for Paroxysmal Supraventricular Tachycardia (PSVT)- Commercial capabilities ...

PDUFA date of March 27, 2025 for CARDAMYST (etripamil) nasal spray for Paroxysmal Supraventricular Tachycardia (PSVT) - Commercial capabilities build out in process, with proposed launch in PSVT targe ...

Milestone plans to initiate a Phase 3 study for the use of etripamil in Atrial Fibrillation with Rapid Ventricular Rate (AFib-RVR) in the first half of 2025. The company is strengthening its ...

Milestone Pharmaceuticals (MIST) provided a corporate update and outlined its strategic priorities for 2025. CARDAMYST for Paroxysmal ...

Three RVR Bank title changes were announced at the recent RVR Bank annual meeting. Tessie Collins was promoted to marketing coordinator, Ashley Kult to retail banking specialist — loan officer ...

Phase 3 pivotal trial in AFib-RVR expected to begin enrollment in H1 2025. Milestone plans to initiate a trial of etripamil nasal spray in patients with AFib-RVR in the at-home setting. The protocol ...

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating and a price target of $25.00 on Milestone Pharmaceuticals, traded on NASDAQ under the ticker (NASDAQ:MIST). The stock has shown strong ...

The safety of abelacimab as compared with a direct oral anticoagulant in patients with atrial fibrillation is unknown. Patients with atrial fibrillation and a moderate-to-high risk of stroke were ...